US EditionPROREIT ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2024 RESULTS
- Nektar Therapeutics reported a fourth-quarter revenue of $29.2 million for 2024, up from $23.9 million in the previous year, with total operating costs decreasing significantly to $14.8 million from $57.4 million.
- Nektar's cash and marketable securities totaled $269.1 million on December 31, 2024, down from $329.4 million a year earlier.
- Howard W. Robin, President and CEO of Nektar, stated that they are on track to report topline data for rezpegaldesleukin in 2025.
- Nektar's net loss for 2024 was $119.0 million, a decrease from a loss of $276.1 million in the previous year.
85 Articles
85 Articles
The Berkshire Eagle
FGI INDUSTRIES ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2024 RESULTS CONFERENCE CALL DATE
EAST HANOVER, N.J., March 13, 2025 /PRNewswire/ -- FGI Industries Ltd. (Nasdaq: FGI) ("FGI" or the "Company"), a leading global supplier of kitchen and bath products, today announced that it will issue financial results for the fourth quarter and full-year…
The State Journal
Vuzix Reports 4Q and Full Year 2024 Financial Results
ROCHESTER, N.Y., March 13, 2025 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI) ("Vuzix" or the "Company"), a leading supplier of AI-driven smart glasses, waveguides and Augmented Reality (AR) technologies, today reported its fourth quarter and full year financial results for the…
Docusign Announces Fourth Quarter and Fiscal Year 2025 Financial Results
SAN FRANCISCO, March 13, 2025 /PRNewswire/ -- Docusign, Inc. (NASDAQ: DOCU) today announced results for its fourth quarter and fiscal year ended January 31, 2025. Prepared remarks and the news release with the financial results will be accessible on Docusign's…
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
